AstraZeneca (LON:AZN) Receives “Buy” Rating from Jefferies Financial Group

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by investment analysts at Jefferies Financial Group in a note issued to investors on Wednesday,Digital Look reports. They currently have a £180 target price on the biopharmaceutical company’s stock. Jefferies Financial Group’s target price indicates a potential upside of 32.02% from the company’s previous close.

Other analysts have also recently issued reports about the company. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating and set a £115 price objective on shares of AstraZeneca in a research report on Wednesday, May 6th. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research note on Thursday, January 15th. Shore Capital Group reaffirmed a “buy” rating on shares of AstraZeneca in a report on Friday, January 16th. Berenberg Bank lifted their price objective on shares of AstraZeneca from £145 to £160 and gave the company a “buy” rating in a research report on Tuesday, January 27th. Finally, Citigroup boosted their price objective on shares of AstraZeneca from £170 to £180 and gave the company a “buy” rating in a research note on Friday, April 10th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, AstraZeneca has a consensus rating of “Moderate Buy” and an average price target of £153.33.

AstraZeneca Trading Down 0.8%

AZN opened at £136.34 on Wednesday. The company has a quick ratio of 0.59, a current ratio of 0.91 and a debt-to-equity ratio of 71.66. AstraZeneca has a 52 week low of GBX 9,932 and a 52 week high of £157.32. The business’s 50 day moving average is £144.48 and its two-hundred day moving average is £140.28. The firm has a market cap of £211.44 billion, a price-to-earnings ratio of 20.53, a price-to-earnings-growth ratio of 0.86 and a beta of 0.22.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.